Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright

Key Points

• HC Wainwright cut Coherus Oncology’s Q3 2026 EPS estimate to a loss of $0.23 per share from $0.18 previously, while forecasting a $0.92-per-share loss for full-year 2026.
• Coherus reported a Q2 loss of $0.19 per share, beating consensus estimates for a $0.25 loss, though revenue of $14.31 million fell slightly short of the $14.41 million forecast.
• Analyst sentiment remains moderately positive, with three Buy ratings and one Hold rating and an average price target of $8.67; however, the stock opened at just $1.20 and has a market capitalization of $185.4 million.

Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Coherus Oncology in a note issued to investors on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the biotechnology company will post earnings per share of ($0.23) for the quarter, down from their prior estimate of ($0.18). The consensus estimate for Coherus Oncology's current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Coherus Oncology's Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at ($0.79) EPS and FY2030 earnings at $0.12 EPS.

Coherus Oncology (NASDAQ:CHRS - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.06. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%.The company had revenue of $14.31 million during the quarter, compared to the consensus estimate of $14.41 million.

A number of other brokerages have also recently issued reports on CHRS. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Coherus Oncology in a research note on Friday, August 7th. Guggenheim assumed coverage on shares of Coherus Oncology in a research report on Monday, May 11th. They issued a "buy" rating and a $12.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Coherus Oncology currently has an average rating of "Moderate Buy" and an average price target of $8.67.

Coherus Oncology Stock Performance

CHRS stock opened at $1.20 on Monday. The company has a market capitalization of $185.40 million, a PE ratio of -1.17 and a beta of 0.98. Coherus Oncology has a one year low of $1.02 and a one year high of $2.62. The company's 50 day moving average price is $1.42 and its two-hundred day moving average price is $1.64. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.70 and a current ratio of 1.77.

Institutional Trading of Coherus Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of CHRS. Acadian Asset Management LLC boosted its stake in shares of Coherus Oncology by 52,980.1% during the first quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 196,556 shares during the period. Geode Capital Management LLC raised its holdings in Coherus Oncology by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,676,476 shares of the biotechnology company's stock valued at $1,958,000 after buying an additional 20,976 shares during the last quarter. XTX Topco Ltd raised its holdings in Coherus Oncology by 65.3% during the 2nd quarter. XTX Topco Ltd now owns 91,739 shares of the biotechnology company's stock valued at $67,000 after buying an additional 36,257 shares during the last quarter. Invesco Ltd. boosted its position in Coherus Oncology by 11.5% during the 2nd quarter. Invesco Ltd. now owns 208,271 shares of the biotechnology company's stock valued at $152,000 after buying an additional 21,550 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Coherus Oncology during the 2nd quarter valued at $46,000. Institutional investors own 72.82% of the company's stock.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company's lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen's Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source